| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000023805 |
| Receipt No. | R000027428 |
| Official scientific title of the study | Effects of pioglitazone on bone formation and resorption markers in type 2 diabetes mellitus. |
| Date of disclosure of the study information | 2016/08/29 |
| Last modified on | 2016/08/29 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Effects of pioglitazone on bone formation and resorption markers in type 2 diabetes mellitus. | |
| Title of the study (Brief title) | Effects of pioglitazone on bone | |
| Region |
|
|
| Condition | ||
| Condition | type 2 diabetes mellitus. | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | we compared the effects of pioglitazone and metformin on bone metabolism in clinical practice using bone metabolic makers, homocystein and pentosidine in Japanese patients with type 2 diabetes mellitus. |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The primary endpoint was changes in bone resorption markers after 3 months by pioglitazone. |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -but assessor(s) are blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | pioglitazone group(males 30 mg/day, females 15 mg/day)
3months |
|
| Interventions/Control_2 | metformin group(750 mg/day)
3months |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | The subjects of this research were male and female type 2 diabetes patients, aged less than 80 years, who attended the First Department of Medicine at the University of Occupational and Environmental Health, Japan, and its associated centers between January 2010 and March 2012. | |||
| Key exclusion criteria | Patients treated with pioglitazone, metformin or insulin, with type 1 diabetes, history of secondary osteoporosis, heart failure, renal failure, liver failure, and patients receiving any drugs that affect bone metabolism (bisphosphonates, vitamin K, estrogen, calcium, anabolic steroids, or male and female hormones) were excluded from the research. | |||
| Target sample size | 60 | |||
| Research contact person | |
| Name of lead principal investigator | Yosuke Okada |
| Organization | University of Occupational and Environmental Health, Japan |
| Division name | First Department of Internal Medicine, School of Medicine |
| Address | 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu-shi 807-8555, Japan |
| TEL | 093-603-1611 |
| y-okada@med.uoeh-u.ac.jp | |
| Public contact | |
| Name of contact person | Hiroko Mori |
| Organization | University of Occupational and Environmental Health, Japan |
| Division name | First Department of Internal Medicine, School of Medicine |
| Address | 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu-shi 807-8555, Japan |
| TEL | 093-603-1611 |
| Homepage URL | |
| morihiro@med.uoeh-u.ac.jp | |
| Sponsor | |
| Institute | University of Occupational and Environmental Health, Japan |
| Institute | |
| Department | |
| Funding Source | |
| Organization | University of Occupational and Environmental Health, Japan |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027428 |